Diabeloop Is 2nd to Win CE Mark for Artificial Pancreas System

Medtronic has a new contender for its MiniMed 670g insulin pump, dubbed the artificial pancreas. The Dublin-based company could see a healthy competitor in Diabeloop, a small firm that recently won CE-mark for DBLG1, a hybrid closed-loop diabetes management system. DLBG1, is a patch work system that uses technologies from different companies to provide glucose measurements every five minutes. The system connects DexCom’s G6 Continuous Glucose Monitor, Kaleido’s patch insulin pump and an algorithm to a user’s phone. DLBG1 has had pretty good data -so far. In June, the company presented data at the American Diabetes Association’s 78th Scientific Sessions at the Orange County Convention Center, that showed the percentage of time spent in the target blood glucose range of 70-180 mg/dl was 69.3% for patients using the DBLG1 system compared to 56.6% for patients using an open-loop system. "With this certification, we're getting closer to the market launch and will move towards a new funding round to support our international scaling and our ambitious R&D roadmap,” Diabeloop co-CEO and CFO said in a release. “We hope to do all that by the second quarter of 2019. Diabeloop noted this was the second CE mark granted to an artificial pancreas-like technology/ Medtronic received a nod for its MiniMed 670g about two years ago. Medtronic’s technology dominated h...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news